NEU 0.00% $1.16 neuren pharmaceuticals limited

IGF-1 molecular pathway

  1. 1,023 Posts.
    lightbulb Created with Sketch. 154
    Treatment for neurodevelopmental and neurodegenerative conditions have proved elusive. The answer to developing effective therapeutics may be at hand.

    "Most importantly, the present data implicate the IGF-1 molecular pathway in the pathogenesis of FXS," excerpt from Abstract, NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome co-authored by Larry Glass.

    Is it simply a case of chasing the right pathway? One problem that investigators face is distinguishing primary from secondary pathways. In CNS disease there are multiple pathways with varying degrees of interdependence. The work by Neuren has focused upon the IGF-1 molecular pathway. Success in current clinical trials could turn future research upon its head. If Neuren is successful in demonstrating the primary importance of the IGF-1 molecular  pathway, it could open the doors to a range of effective therapies.

    For instance, investigators have been chasing a cure for Alzheimer's disease by focusing upon amyloid plaque formation. It is undoubtedly a relevant target but could success be contingent upon finding a therapy to address other pathways in the disease!

    Its not a case of Tofinetide being a panacea but rather a key therapy in unlocking the complex interdependent multiple pathways in CNS disease.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$1.16
Change
0.000(0.00%)
Mkt cap ! $121.1M
Open High Low Value Volume
$1.16 $1.16 $1.15 $105.3K 91.11K

Buyers (Bids)

No. Vol. Price($)
2 5872 $1.15
 

Sellers (Offers)

Price($) Vol. No.
$1.16 16356 1
View Market Depth
Last update - 15.59pm 19/03/2019 (20 minute delay) ?
(live)
Last
$1.16
  Change
0.000 ( 0.86 %)
Open High Low Volume
$1.15 $1.16 $1.15 4561
Last updated 14.00pm 19/03/2019 (live) ?
NEU (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.